melphalan zentiva 50 mg prášok a rozpúšťadlo na injekčný/infúzny roztok
zentiva k.s., Česká republika - melfalán - 44 - cytostatica
botox 50 allergan units
abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia
systém implantovateľný alphatec solus
alphatec spine inc. 5818 el camino real ca 92008 carlsbad, ca spojené štáty americké -
enzepi
allergan pharmaceuticals international ltd - pankreasový prášok - exokrinná nedostatočnosť pankreasu - tráviace prostriedky, vrátane enzýmy - liečba nahradzovania pankreatických enzýmov pri exokrinnej nedostatočnosti pankreasu v dôsledku cystickej fibrózy alebo iných stavov (e. chronická pankreatitída, pankreatektómia alebo rakovina pankreasu). enzepi je uvedené v dojčatá, deti, dospievajúci a dospelí.
botox 100 allergan units
abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia
panzytrat 10 000
allergan pharmaceuticals international ltd., Írsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastické činidlá - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - viacnásobný myelóm - antineoplastické činidlá - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
truberzi
allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrheals, črevné protizápalové / antiinfective agentov - truberzi je indikovaný u dospelých na liečbu syndrómu dráždivého čreva s hnačkou (ibs d).
cellufluid
abbvie s.r.o., slovensko - umelé slzy a iné indiferentné liečivá - 64 - ophthalmologica